BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matsumoto M, Hada N, Sakamaki Y, Uno A, Shiga T, Tanaka C, Ito T, Katsume A, Sudoh M. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Pathol. 2013;94:93-103. [PMID: 23305254 DOI: 10.1111/iep.12008] [Cited by in Crossref: 153] [Cited by in F6Publishing: 144] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Suga T, Yamaguchi H, Ogura J, Shoji S, Maekawa M, Mano N. Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis. Toxicol Appl Pharmacol 2019;379:114664. [PMID: 31306673 DOI: 10.1016/j.taap.2019.114664] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
2 Nakamoto K, Shimada K, Harada S, Morimoto Y, Hirasawa A, Tokuyama S. DHA supplementation prevent the progression of NASH via GPR120 signaling. Eur J Pharmacol 2018;820:31-8. [PMID: 29221950 DOI: 10.1016/j.ejphar.2017.11.046] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
3 Saif M, Kwanten WJ, Carr JA, Chen IX, Posada JM, Srivastava A, Zhang J, Zheng Y, Pinter M, Chatterjee S, Softic S, Kahn CR, van Leyen K, Bruns OT, Jain RK, Bawendi MG. Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin. Nat Biomed Eng 2020;4:801-13. [PMID: 32572196 DOI: 10.1038/s41551-020-0569-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
4 Kawachi Y, Fujishima Y, Nishizawa H, Nakamura T, Akari S, Murase T, Saito T, Miyazaki Y, Nagao H, Fukuda S, Kita S, Katakami N, Doki Y, Maeda N, Shimomura I. Increased plasma XOR activity induced by NAFLD/NASH and its possible involvement in vascular neointimal proliferation. JCI Insight 2021;6:144762. [PMID: 34494551 DOI: 10.1172/jci.insight.144762] [Reference Citation Analysis]
5 Ejima C, Kuroda H, Ishizaki S. A novel diet-induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis. Physiol Rep 2016;4:e13016. [PMID: 27821715 DOI: 10.14814/phy2.13016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
6 Luther J, Gala MK, Borren N, Masia R, Goodman RP, Moeller IH, DiGiacomo E, Ehrlich A, Warren A, Yarmush ML, Ananthakrishnan A, Corey K, Kaplan LM, Bhatia S, Chung RT, Patel SJ. Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity. Hepatol Commun 2018;2:786-97. [PMID: 30202815 DOI: 10.1002/hep4.1179] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
7 Pandit H, Tinney JP, Li Y, Cui G, Li S, Keller BB, Martin RC. Utilizing Contrast-Enhanced Ultrasound Imaging for Evaluating Fatty Liver Disease Progression in Pre-clinical Mouse Models. Ultrasound in Medicine & Biology 2019;45:549-57. [DOI: 10.1016/j.ultrasmedbio.2018.10.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Amano Y, Shimizu F, Yasuno H, Harada A, Tsuchiya S, Isono O, Nagabukuro H, Tozawa R. Non-alcoholic steatohepatitis-associated hepatic fibrosis and hepatocellular carcinoma in a combined mouse model of genetic modification and dietary challenge. Hepatol Res 2017;47:103-15. [PMID: 26992446 DOI: 10.1111/hepr.12709] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Flores-Costa R, Duran-Güell M, Casulleras M, López-Vicario C, Alcaraz-Quiles J, Diaz A, Lozano JJ, Titos E, Hall K, Sarno R, Masferrer JL, Clària J. Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP/NF-κB/NLRP3 inflammasome circuit. Proc Natl Acad Sci U S A 2020;117:28263-74. [PMID: 33106416 DOI: 10.1073/pnas.2000466117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Yao Q, Li S, Li X, Wang F, Tu C. Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis. Front Med 2020;7:71. [DOI: 10.3389/fmed.2020.00071] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
11 Seidman JS, Troutman TD, Sakai M, Gola A, Spann NJ, Bennett H, Bruni CM, Ouyang Z, Li RZ, Sun X, Vu BT, Pasillas MP, Ego KM, Gosselin D, Link VM, Chong LW, Evans RM, Thompson BM, McDonald JG, Hosseini M, Witztum JL, Germain RN, Glass CK. Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis. Immunity 2020;52:1057-1074.e7. [PMID: 32362324 DOI: 10.1016/j.immuni.2020.04.001] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 29.5] [Reference Citation Analysis]
12 Guarino M, Kumar P, Felser A, Terracciano LM, Guixé-Muntet S, Humar B, Foti M, Nuoffer JM, St-Pierre MV, Dufour JF. Exercise Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation in Mice. Cancers (Basel) 2020;12:E1407. [PMID: 32486073 DOI: 10.3390/cancers12061407] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
13 Nevzorova YA, Boyer-diaz Z, Cubero FJ, Gracia-sancho J. Animal models for liver disease – A practical approach for translational research. Journal of Hepatology 2020;73:423-40. [DOI: 10.1016/j.jhep.2020.04.011] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 18.5] [Reference Citation Analysis]
14 Kakehashi A, Chariyakornkul A, Suzuki S, Khuanphram N, Tatsumi K, Yamano S, Fujioka M, Gi M, Wongpoomchai R, Wanibuchi H. Cache Domain Containing 1 Is a Novel Marker of Non-Alcoholic Steatohepatitis-Associated Hepatocarcinogenesis. Cancers (Basel) 2021;13:1216. [PMID: 33802238 DOI: 10.3390/cancers13061216] [Reference Citation Analysis]
15 Takatani N, Kono Y, Beppu F, Okamatsu-Ogura Y, Yamano Y, Miyashita K, Hosokawa M. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice. Biochem Biophys Res Commun 2020;528:305-10. [PMID: 32475638 DOI: 10.1016/j.bbrc.2020.05.050] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
16 Suzuki-Kemuriyama N, Abe A, Uno K, Ogawa S, Watanabe A, Sano R, Yuki M, Miyajima K, Nakae D. A trans fatty acid substitute enhanced development of liver proliferative lesions induced in mice by feeding a choline-deficient, methionine-lowered, L-amino acid-defined, high-fat diet. Lipids Health Dis 2020;19:251. [PMID: 33317575 DOI: 10.1186/s12944-020-01423-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Mohan H, Brandt SL, Kim JH, Wong F, Lai M, Prentice KJ, Al Rijjal D, Magomedova L, Batchuluun B, Burdett E, Bhattacharjee A, Cummins CL, Belsham DD, Cox B, Liu Y, Wheeler MB. 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) prevents high fat diet-induced insulin resistance via maintenance of hepatic lipid homeostasis. Diabetes Obes Metab 2019;21:61-72. [PMID: 30062833 DOI: 10.1111/dom.13483] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
18 Rahmadi M, Nurhan AD, Pratiwi ED, Prameswari DA, Panggono SM, Nisak K, Khotib J. The effect of various high-fat diet on liver histology in the development of NAFLD models in mice. J Basic Clin Physiol Pharmacol 2021;32:547-53. [PMID: 34214382 DOI: 10.1515/jbcpp-2020-0426] [Reference Citation Analysis]
19 Chen S, He Z, Xie W, Chen X, Lin Z, Ma J, Liu Z, Yang S, Wang Y. Ginsenoside Rh2 attenuates CDAHFD-induced liver fibrosis in mice by improving intestinal microbial composition and regulating LPS-mediated autophagy. Phytomedicine 2022;101:154121. [PMID: 35489327 DOI: 10.1016/j.phymed.2022.154121] [Reference Citation Analysis]
20 Hoffmann C, Djerir NEH, Danckaert A, Fernandes J, Roux P, Charrueau C, Lachagès AM, Charlotte F, Brocheriou I, Clément K, Aron-Wisnewsky J, Foufelle F, Ratziu V, Hainque B, Bonnefont-Rousselot D, Bigey P, Escriou V. Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis. Sci Rep 2020;10:3850. [PMID: 32123215 DOI: 10.1038/s41598-020-60615-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
21 Lin L, Li Y, Zhou G, Wang Y, Li L, Han J, Chen M, He Y, Zhang S. Multi-Omics Analysis of Western-style Diet Increased Susceptibility to Experimental Colitis in Mice. JIR 2022;Volume 15:2523-37. [DOI: 10.2147/jir.s361039] [Reference Citation Analysis]
22 Tokinoya K, Sekine N, Aoki K, Ono S, Kuji T, Sugasawa T, Yoshida Y, Takekoshi K. Effects of renalase deficiency on liver fibrosis markers in a nonalcoholic steatohepatitis mouse model. Mol Med Rep 2021;23:210. [PMID: 33495844 DOI: 10.3892/mmr.2021.11849] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908-922. [PMID: 29967350 DOI: 10.1038/s41591-018-0104-9] [Cited by in Crossref: 777] [Cited by in F6Publishing: 742] [Article Influence: 194.3] [Reference Citation Analysis]
24 Fraser DA, Wang X, Lund J, Nikolić N, Iruarrizaga-Lejarreta M, Skjaeret T, Alonso C, Kastelein JJP, Rustan AC, Kim YO, Schuppan D. A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. J Hepatol 2021:S0168-8278(21)02244-3. [PMID: 34915054 DOI: 10.1016/j.jhep.2021.12.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Chikada H, Ida K, Nishikawa Y, Inagaki Y, Kamiya A. Liver-specific knockout of B cell lymphoma 6 suppresses progression of non-alcoholic steatohepatitis in mice. Sci Rep 2020;10:9704. [PMID: 32546802 DOI: 10.1038/s41598-020-66539-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Xia SF, Jiang YY, Qiu YY, Huang W, Wang J. Role of diets and exercise in ameliorating obesity-related hepatic steatosis: Insights at the microRNA-dependent thyroid hormone synthesis and action. Life Sci 2020;242:117182. [PMID: 31863770 DOI: 10.1016/j.lfs.2019.117182] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
27 Rokugawa T, Konishi H, Ito M, Iimori H, Nagai R, Shimosegawa E, Hatazawa J, Abe K. Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by 18F-FPP-RGD2 PET. EJNMMI Res 2018;8:40. [PMID: 29855729 DOI: 10.1186/s13550-018-0394-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
28 Lin H, Wang L, Liu Z, Long K, Kong M, Ye D, Chen X, Wang K, Wu KK, Fan M, Song E, Wang C, Hoo RL, Hui X, Hallenborg P, Piao H, Xu A, Cheng KK. Hepatic MDM2 Causes Metabolic Associated Fatty Liver Disease by Blocking Triglyceride-VLDL Secretion via ApoB Degradation. Adv Sci (Weinh) 2022;:e2200742. [PMID: 35524581 DOI: 10.1002/advs.202200742] [Reference Citation Analysis]
29 Reid DT, Eksteen B. Murine models provide insight to the development of non-alcoholic fatty liver disease. Nutr Res Rev. 2015;28:133-142. [PMID: 26494024 DOI: 10.1017/s0954422415000128] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
30 Puengel T, Lefere S, Hundertmark J, Kohlhepp M, Penners C, Van de Velde F, Lapauw B, Hoorens A, Devisscher L, Geerts A, Boehm S, Zhao Q, Krupinski J, Charles ED, Zinker B, Tacke F. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis. Int J Mol Sci 2022;23:6696. [PMID: 35743140 DOI: 10.3390/ijms23126696] [Reference Citation Analysis]
31 Kobayashi T, Kanno K, Nguyen PT, Sugiyama A, Kawahara A, Otani Y, Kishikawa N, Ito M, Tazuma S. Periostin antisense oligonucleotide prevents hepatic steatosis and fibrosis in a mouse model of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2020;35:2140-50. [PMID: 32365405 DOI: 10.1111/jgh.15088] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Tsurusaki S, Tsuchiya Y, Koumura T, Nakasone M, Sakamoto T, Matsuoka M, Imai H, Yuet-Yin Kok C, Okochi H, Nakano H, Miyajima A, Tanaka M. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis. Cell Death Dis 2019;10:449. [PMID: 31209199 DOI: 10.1038/s41419-019-1678-y] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 20.0] [Reference Citation Analysis]
33 Xiong J, Liu T, Mi L, Kuang H, Xiong X, Chen Z, Li S, Lin JD. hnRNPU/TrkB Defines a Chromatin Accessibility Checkpoint for Liver Injury and Nonalcoholic Steatohepatitis Pathogenesis. Hepatology 2020;71:1228-46. [PMID: 31469911 DOI: 10.1002/hep.30921] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
34 Yang M, Kimchi ET, Staveley-O'Carroll KF, Li G. Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity. Int J Mol Sci 2021;22:11037. [PMID: 34681695 DOI: 10.3390/ijms222011037] [Reference Citation Analysis]
35 Preguiça I, Alves A, Nunes S, Fernandes R, Gomes P, Viana SD, Reis F. Diet-induced rodent models of obesity-related metabolic disorders-A guide to a translational perspective. Obes Rev 2020;21:e13081. [PMID: 32691524 DOI: 10.1111/obr.13081] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
36 Saigo Y, Sasase T, Uno K, Shinozaki Y, Maekawa T, Sano R, Toriniwa Y, Miyajima K, Ohta T. Establishment of a new nonalcoholic steatohepatitis model; Ovariectomy exacerbates nonalcoholic steatohepatitis-like pathology in diabetic rats. Journal of Pharmacological and Toxicological Methods 2022. [DOI: 10.1016/j.vascn.2022.107190] [Reference Citation Analysis]
37 Alsamman S, Christenson SA, Yu A, Ayad NME, Mooring MS, Segal JM, Hu JK, Schaub JR, Ho SS, Rao V, Marlow MM, Turner SM, Sedki M, Pantano L, Ghoshal S, Ferreira DDS, Ma HY, Duwaerts CC, Espanol-Suner R, Wei L, Newcomb B, Mileva I, Canals D, Hannun YA, Chung RT, Mattis AN, Fuchs BC, Tager AM, Yimlamai D, Weaver VM, Mullen AC, Sheppard D, Chen JY. Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice. Sci Transl Med 2020;12:eaay8798. [PMID: 32817366 DOI: 10.1126/scitranslmed.aay8798] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 18.0] [Reference Citation Analysis]
38 Lee S, Kwak JH, Kim SH, Jeong TB, Son SW, Kim JH, Lim Y, Cho JY, Hwang DY, Kim KS, Jung YS. Comparative study of liver injury induced by high-fat methionine- and choline-deficient diet in ICR mice originating from three different sources. Lab Anim Res 2019;35:15. [PMID: 32257903 DOI: 10.1186/s42826-019-0016-y] [Reference Citation Analysis]
39 Susutlertpanya W, Wakuda H, Otani N, Kuramoto T, Li L, Kuranari M, Sekiguchi A, Kudo H, Uchida T, Imai H, Uemura N. Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice. Life Sciences 2019;228:251-7. [DOI: 10.1016/j.lfs.2019.05.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
40 Xiong X, Kuang H, Ansari S, Liu T, Gong J, Wang S, Zhao XY, Ji Y, Li C, Guo L, Zhou L, Chen Z, Leon-Mimila P, Chung MT, Kurabayashi K, Opp J, Campos-Pérez F, Villamil-Ramírez H, Canizales-Quinteros S, Lyons R, Lumeng CN, Zhou B, Qi L, Huertas-Vazquez A, Lusis AJ, Xu XZS, Li S, Yu Y, Li JZ, Lin JD. Landscape of Intercellular Crosstalk in Healthy and NASH Liver Revealed by Single-Cell Secretome Gene Analysis. Mol Cell 2019;75:644-660.e5. [PMID: 31398325 DOI: 10.1016/j.molcel.2019.07.028] [Cited by in Crossref: 148] [Cited by in F6Publishing: 148] [Article Influence: 74.0] [Reference Citation Analysis]
41 Castro RE, Diehl AM. Towards a definite mouse model of NAFLD. Journal of Hepatology 2018;69:272-4. [DOI: 10.1016/j.jhep.2018.05.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
42 [DOI: 10.1101/2021.03.22.436368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Bae CR, Zhang H, Kwon YG. The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice. PLoS One 2020;15:e0243497. [PMID: 33275637 DOI: 10.1371/journal.pone.0243497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Waghorn PA, Ferreira DS, Erstad DJ, Rotile NJ, Masia R, Jones CM, Tu C, Sojoodi M, Chen YI, Schlerman F, Wellen J, Martinez RVP, Tanabe KK, Fuchs BC, Caravan P. Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis. Sci Rep 2021;11:6105. [PMID: 33731798 DOI: 10.1038/s41598-021-85679-4] [Reference Citation Analysis]
45 Haberl EM, Pohl R, Rein-Fischboeck L, Höring M, Krautbauer S, Liebisch G, Buechler C. Hepatic lipid profile in mice fed a choline-deficient, low-methionine diet resembles human non-alcoholic fatty liver disease. Lipids Health Dis 2020;19:250. [PMID: 33298075 DOI: 10.1186/s12944-020-01425-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
46 Ikawa-Yoshida A, Matsuo S, Kato A, Ohmori Y, Higashida A, Kaneko E, Matsumoto M. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet. Int J Exp Pathol 2017;98:221-33. [PMID: 28895242 DOI: 10.1111/iep.12240] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
47 Laitakari A, Tapio J, Mäkelä KA, Herzig KH, Dengler F, Gylling H, Walkinshaw G, Myllyharju J, Dimova EY, Serpi R, Koivunen P. HIF-P4H-2 inhibition enhances intestinal fructose metabolism and induces thermogenesis protecting against NAFLD. J Mol Med (Berl) 2020;98:719-31. [PMID: 32296880 DOI: 10.1007/s00109-020-01903-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
48 de la Rosa Rodriguez MA, Deng L, Gemmink A, van Weeghel M, Aoun ML, Warnecke C, Singh R, Borst JW, Kersten S. Hypoxia-inducible lipid droplet-associated induces DGAT1 and promotes lipid storage in hepatocytes. Mol Metab 2021;47:101168. [PMID: 33465519 DOI: 10.1016/j.molmet.2021.101168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
49 Perakakis N, Ghaly W, Peradze N, Boutari C, Batirel S, Douglas VP, Mantzoros CS. Research advances in metabolism 2017. Metabolism 2018;83:280-9. [PMID: 29378200 DOI: 10.1016/j.metabol.2018.01.018] [Reference Citation Analysis]
50 Reimer KC, Wree A, Roderburg C, Tacke F. New drugs for NAFLD: lessons from basic models to the clinic. Hepatol Int 2020;14:8-23. [PMID: 31802390 DOI: 10.1007/s12072-019-10001-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
51 Simoes ICM, Janikiewicz J, Bauer J, Karkucinska-Wieckowska A, Kalinowski P, Dobrzyń A, Wolski A, Pronicki M, Zieniewicz K, Dobrzyń P, Krawczyk M, Zischka H, Wieckowski MR, Potes Y. Fat and Sugar-A Dangerous Duet. A Comparative Review on Metabolic Remodeling in Rodent Models of Nonalcoholic Fatty Liver Disease. Nutrients 2019;11:E2871. [PMID: 31771244 DOI: 10.3390/nu11122871] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
52 Bae CR, Hino J, Hosoda H, Miyazato M, Kangawa K. C-type natriuretic peptide (CNP) in endothelial cells attenuates hepatic fibrosis and inflammation in non-alcoholic steatohepatitis. Life Sci 2018;209:349-56. [PMID: 30114411 DOI: 10.1016/j.lfs.2018.08.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
53 Vacca M, Leslie J, Virtue S, Lam BYH, Govaere O, Tiniakos D, Snow S, Davies S, Petkevicius K, Tong Z, Peirce V, Nielsen MJ, Ament Z, Li W, Kostrzewski T, Leeming DJ, Ratziu V, Allison MED, Anstee QM, Griffin JL, Oakley F, Vidal-Puig A. Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis. Nat Metab 2020;2:514-31. [PMID: 32694734 DOI: 10.1038/s42255-020-0214-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
54 Kroh A, Ivanova V, Drescher H, Andruszkow J, Longerich T, Nolting J, Eickhoff R, Heise D, Rheinwalt KP, Neumann UP, Ulmer FT. Mouse Models of Nonalcoholic Steatohepatitis: Head-to-Head Comparison of Dietary Models and Impact on Inflammation and Animal Welfare. Gastroenterol Res Pract 2020;2020:7347068. [PMID: 32765601 DOI: 10.1155/2020/7347068] [Reference Citation Analysis]
55 Choi EY, Choi JO, Park CY, Kim SH, Kim D. Water Extract of Artemisia annua L. Exhibits Hepatoprotective Effects Through Improvement of Lipid Accumulation and Oxidative Stress-Induced Cytotoxicity. J Med Food 2020;23:1312-22. [PMID: 33202166 DOI: 10.1089/jmf.2020.4696] [Reference Citation Analysis]
56 Ookawara M, Matsuda K, Watanabe M, Moritoh Y. The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight. J Pharmacol Exp Ther. 2020;375:21-27. [PMID: 32719069 DOI: 10.1124/jpet.120.000046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Zheng Q, Martin RC, Shi X, Pandit H, Yu Y, Liu X, Guo W, Tan M, Bai O, Meng X, Li Y. Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling. Theranostics 2020;10:9923-36. [PMID: 32929325 DOI: 10.7150/thno.45988] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
58 Pierantonelli I, Svegliati-baroni G. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. Transplantation 2019;103:e1-e13. [DOI: 10.1097/tp.0000000000002480] [Cited by in Crossref: 73] [Cited by in F6Publishing: 50] [Article Influence: 24.3] [Reference Citation Analysis]
59 Keller LM, Eighmy S, Li C, Winter L, Kerecman J, Goodman Z, Mittal N, Blanco CL. Association of novel markers of liver disease with neonatal liver disease in premature baboons, Papio sp. PLoS One 2020;15:e0228985. [PMID: 32150543 DOI: 10.1371/journal.pone.0228985] [Reference Citation Analysis]
60 Uchio R, Murosaki S, Ichikawa H. Hot water extract of turmeric (Curcuma longa) prevents non-alcoholic steatohepatitis in mice by inhibiting hepatic oxidative stress and inflammation. J Nutr Sci 2018;7:e36. [PMID: 30627433 DOI: 10.1017/jns.2018.27] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
61 Loft A, Alfaro AJ, Schmidt SF, Pedersen FB, Terkelsen MK, Puglia M, Chow KK, Feuchtinger A, Troullinaki M, Maida A, Wolff G, Sakurai M, Berutti R, Ekim Üstünel B, Nawroth P, Ravnskjaer K, Diaz MB, Blagoev B, Herzig S. Liver-fibrosis-activated transcriptional networks govern hepatocyte reprogramming and intra-hepatic communication. Cell Metab 2021;33:1685-1700.e9. [PMID: 34237252 DOI: 10.1016/j.cmet.2021.06.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Ulmasov B, Noritake H, Carmichael P, Oshima K, Griggs DW, Neuschwander-Tetri BA. An Inhibitor of Arginine-Glycine-Aspartate-Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis. Hepatol Commun 2019;3:246-61. [PMID: 30766962 DOI: 10.1002/hep4.1298] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
63 Sugimoto M, Hamada T, Wakabayasi M, Yoshioka T, Kato H, Konishi H, Nagai R, Suzuki M, Numata Y, Igarashi Y, Yukioka H. Sphingomyelin synthase 2 loss suppresses steatosis but exacerbates fibrosis in the liver of mice fed with choline-deficient, L-amino acid-defined, high-fat diet. Biochem Biophys Res Commun 2020;533:1269-75. [PMID: 33059919 DOI: 10.1016/j.bbrc.2020.09.142] [Reference Citation Analysis]
64 Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16:411-428. [PMID: 31028350 DOI: 10.1038/s41575-019-0145-7] [Cited by in Crossref: 268] [Cited by in F6Publishing: 286] [Article Influence: 89.3] [Reference Citation Analysis]
65 Cho CS, Park HW, Ho A, Semple IA, Kim B, Jang I, Park H, Reilly S, Saltiel AR, Lee JH. Lipotoxicity induces hepatic protein inclusions through TANK binding kinase 1-mediated p62/sequestosome 1 phosphorylation. Hepatology 2018;68:1331-46. [PMID: 29251796 DOI: 10.1002/hep.29742] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 11.0] [Reference Citation Analysis]
66 Gosis BS, Wada S, Thorsheim C, Li K, Jung S, Rhoades JH, Yang Y, Brandimarto J, Li L, Uehara K, Jang C, Lanza M, Sanford NB, Bornstein MR, Jeong S, Titchenell PM, Biddinger SB, Arany Z. Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1. Science 2022;376:eabf8271. [PMID: 35420934 DOI: 10.1126/science.abf8271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Wolf MJ, Adili A, Piotrowitz K, Abdullah Z, Boege Y, Stemmer K, Ringelhan M, Simonavicius N, Egger M, Wohlleber D. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell. 2014;26:549-564. [PMID: 25314080 DOI: 10.1016/j.ccell.2014.09.003] [Cited by in Crossref: 297] [Cited by in F6Publishing: 289] [Article Influence: 37.1] [Reference Citation Analysis]
68 Bao YL, Wang L, Pan HT, Zhang TR, Chen YH, Xu SJ, Mao XL, Li SW. Animal and Organoid Models of Liver Fibrosis. Front Physiol 2021;12:666138. [PMID: 34122138 DOI: 10.3389/fphys.2021.666138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Delire B, Stärkel P, Leclercq I. Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development. J Clin Transl Hepatol 2015;3:53-66. [PMID: 26357635 DOI: 10.14218/JCTH.2014.00035] [Cited by in Crossref: 72] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
70 Ichimura M, Masuzumi M, Kawase M, Sakaki M, Tamaru S, Nagata Y, Tanaka K, Suruga K, Tsuneyama K, Matsuda S, Omagari K. A diet-induced Sprague-Dawley rat model of nonalcoholic steatohepatitis-related cirrhosis. J Nutr Biochem 2017;40:62-9. [PMID: 27863346 DOI: 10.1016/j.jnutbio.2016.10.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
71 Honda T, Ishigami M, Luo F, Lingyun M, Ishizu Y, Kuzuya T, Hayashi K, Nakano I, Ishikawa T, Feng GG, Katano Y, Kohama T, Kitaura Y, Shimomura Y, Goto H, Hirooka Y. Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice. Metabolism. 2017;69:177-187. [PMID: 28285648 DOI: 10.1016/j.metabol.2016.12.013] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
72 Bahabadi M, Mohammadalipour A, Karimi J, Sheikh N, Solgi G, Goudarzi F, Hashemnia M, Khodadadi I. Hepatoprotective effect of parthenolide in rat model of nonalcoholic fatty liver disease. Immunopharmacology and Immunotoxicology 2017;39:233-42. [DOI: 10.1080/08923973.2017.1327965] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
73 Soret PA, Magusto J, Housset C, Gautheron J. In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal. J Clin Med 2020;10:E36. [PMID: 33374435 DOI: 10.3390/jcm10010036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Longo L, Tonin Ferrari J, Rampelotto PH, Hirata Dellavia G, Pasqualotto A, P Oliveira C, Thadeu Schmidt Cerski C, Reverbel da Silveira T, Uribe-Cruz C, Álvares-da-Silva MR. Gut Dysbiosis and Increased Intestinal Permeability Drive microRNAs, NLRP-3 Inflammasome and Liver Fibrosis in a Nutritional Model of Non-Alcoholic Steatohepatitis in Adult Male Sprague Dawley Rats. Clin Exp Gastroenterol 2020;13:351-68. [PMID: 32982365 DOI: 10.2147/CEG.S262879] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
75 Yoo T, Joo SK, Kim HJ, Kim HY, Sim H, Lee J, Kim HH, Jung S, Lee Y, Jamialahmadi O, Romeo S, Jeong WI, Hwang GS, Kang KW, Kim JW, Kim W, Choi M; Innovative Target Exploration of NAFLD (ITEN) consortium. Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease. J Hepatol 2021;75:514-23. [PMID: 33892010 DOI: 10.1016/j.jhep.2021.04.011] [Reference Citation Analysis]
76 Kim BM, Abdelfattah AM, Vasan R, Fuchs BC, Choi MY. Hepatic stellate cells secrete Ccl5 to induce hepatocyte steatosis. Sci Rep 2018;8:7499. [PMID: 29760499 DOI: 10.1038/s41598-018-25699-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
77 Patel V, Joharapurkar A, Kshirsagar S, Patel M, Sutariya B, Patel H, Pandey D, Patel D, Ranvir R, Kadam S, Bahekar R, Jain M. Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease. Can J Physiol Pharmacol. 2018;96:587-596. [PMID: 29406832 DOI: 10.1139/cjpp-2017-0683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
78 Jiang X, Li X, Feng W, Qin Y, Li Z, Nie H, Qin W, Han L, Bai W. Baking of methionine-choline deficient diet aggravates testis injury in mice. Food Chem Toxicol 2021;154:112245. [PMID: 33940107 DOI: 10.1016/j.fct.2021.112245] [Reference Citation Analysis]
79 Pusec CM, De Jesus A, Khan MW, Terry AR, Ludvik AE, Xu K, Giancola N, Pervaiz H, Daviau Smith E, Ding X, Harrison S, Chandel NS, Becker TC, Hay N, Ardehali H, Cordoba-Chacon J, Layden BT. Hepatic HKDC1 Expression Contributes to Liver Metabolism. Endocrinology 2019;160:313-30. [PMID: 30517626 DOI: 10.1210/en.2018-00887] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
80 Tølbøl KS, Stierstorfer B, Rippmann JF, Veidal SS, Rigbolt KTG, Schönberger T, Gillum MP, Hansen HH, Vrang N, Jelsing J, Feigh M, Broermann A. Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis. Dig Dis Sci 2019;64:1238-56. [PMID: 30511198 DOI: 10.1007/s10620-018-5395-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
81 Rajak S, Gupta P, Anjum B, Raza S, Tewari A, Ghosh S, Tripathi M, Singh BK, Sinha RA. Role of AKR1B10 and AKR1B8 in the pathogenesis of non-alcoholic steatohepatitis (NASH) in mouse. Biochim Biophys Acta Mol Basis Dis 2021;:166319. [PMID: 34954342 DOI: 10.1016/j.bbadis.2021.166319] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Horai Y, Utsumi H, Ono Y, Kishimoto T, Ono Y, Fukunari A. Pathological characterization and morphometric analysis of hepatic lesions in SHRSP5/Dmcr, an experimental non-alcoholic steatohepatitis model, induced by high-fat and high-cholesterol diet. Int J Exp Pathol 2016;97:75-85. [PMID: 27037502 DOI: 10.1111/iep.12169] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
83 Leng YR, Zhang MH, Luo JG, Zhang H. Pathogenesis of NASH and Promising Natural Products. Chin J Nat Med 2021;19:12-27. [PMID: 33516448 DOI: 10.1016/S1875-5364(21)60002-X] [Reference Citation Analysis]
84 Dungubat E, Watabe S, Togashi-Kumagai A, Watanabe M, Kobayashi Y, Harada N, Yamaji R, Fukusato T, Lodon G, Sevjid B, Takahashi Y. Effects of Caffeine and Chlorogenic Acid on Nonalcoholic Steatohepatitis in Mice Induced by Choline-Deficient, L-Amino Acid-Defined, High-Fat Diet. Nutrients 2020;12:E3886. [PMID: 33353230 DOI: 10.3390/nu12123886] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
85 Tutusaus A, de Gregorio E, Cucarull B, Cristóbal H, Aresté C, Graupera I, Coll M, Colell A, Gausdal G, Lorens JB, García de Frutos P, Morales A, Marí M. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target. Cell Mol Gastroenterol Hepatol 2020;9:349-68. [PMID: 31689560 DOI: 10.1016/j.jcmgh.2019.10.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
86 Omori S, Wang TW, Johmura Y, Kanai T, Nakano Y, Kido T, Susaki EA, Nakajima T, Shichino S, Ueha S, Ozawa M, Yokote K, Kumamoto S, Nishiyama A, Sakamoto T, Yamaguchi K, Hatakeyama S, Shimizu E, Katayama K, Yamada Y, Yamazaki S, Iwasaki K, Miyoshi C, Funato H, Yanagisawa M, Ueno H, Imoto S, Furukawa Y, Yoshida N, Matsushima K, Ueda HR, Miyajima A, Nakanishi M. Generation of a p16 Reporter Mouse and Its Use to Characterize and Target p16high Cells In Vivo. Cell Metab 2020;32:814-828.e6. [PMID: 32949498 DOI: 10.1016/j.cmet.2020.09.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
87 Kruger AJ, Fuchs BC, Masia R, Holmes JA, Salloum S, Sojoodi M, Ferreira DS, Rutledge SM, Caravan P, Alatrakchi N. Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis. Hepatol Commun. 2018;2:529-545. [PMID: 29761169 DOI: 10.1002/hep4.1160] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
88 Min-DeBartolo J, Schlerman F, Akare S, Wang J, McMahon J, Zhan Y, Syed J, He W, Zhang B, Martinez RV. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH). PLoS One 2019;14:e0226854. [PMID: 31891606 DOI: 10.1371/journal.pone.0226854] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
89 Nagashimada M, Honda M. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics. Int J Mol Sci 2021;22:8008. [PMID: 34360773 DOI: 10.3390/ijms22158008] [Reference Citation Analysis]
90 De Rudder M, Bouzin C, Nachit M, Louvegny H, Vande Velde G, Julé Y, Leclercq IA. Automated computerized image analysis for the user-independent evaluation of disease severity in preclinical models of NAFLD/NASH. Lab Invest 2020;100:147-60. [PMID: 31506634 DOI: 10.1038/s41374-019-0315-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
91 Ni Y, Zhuge F, Nagashimada M, Ota T. Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis. Nutrients. 2016;8:pii: E391. [PMID: 27347998 DOI: 10.3390/nu8070391] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
92 Kim S, Park MR, Choi C, Kim JB, Cha C. Synergistic control of mechanics and microarchitecture of 3D bioactive hydrogel platform to promote the regenerative potential of engineered hepatic tissue. Biomaterials 2021;270:120688. [PMID: 33549994 DOI: 10.1016/j.biomaterials.2021.120688] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
93 Okuno T, Kakehashi A, Ishii N, Fujioka M, Gi M, Wanibuchi H. mTOR Activation in Liver Tumors Is Associated with Metabolic Syndrome and Non-Alcoholic Steatohepatitis in Both Mouse Models and Humans. Cancers (Basel) 2018;10:E465. [PMID: 30469530 DOI: 10.3390/cancers10120465] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
94 Kisoh K, Sugahara G, Ogawa Y, Furukawa S, Ishida Y, Okanoue T, Kohara M, Tateno C. Estimating Drug Efficacy with a Diet-Induced NASH Model in Chimeric Mice with Humanized Livers. Biomedicines 2021;9:1647. [PMID: 34829876 DOI: 10.3390/biomedicines9111647] [Reference Citation Analysis]
95 Jain MR, Giri SR, Bhoi B, Trivedi C, Rath A, Rathod R, Ranvir R, Kadam S, Patel H, Swain P, Roy SS, Das N, Karmakar E, Wahli W, Patel PR. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int 2018;38:1084-94. [PMID: 29164820 DOI: 10.1111/liv.13634] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 14.4] [Reference Citation Analysis]
96 Horas H Nababan S, Nishiumi S, Kawano Y, Kobayashi T, Yoshida M, Azuma T. Adrenic acid as an inflammation enhancer in non-alcoholic fatty liver disease. Archives of Biochemistry and Biophysics 2017;623-624:64-75. [DOI: 10.1016/j.abb.2017.04.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
97 Nishimichi N, Tsujino K, Kanno K, Sentani K, Kobayashi T, Chayama K, Sheppard D, Yokosaki Y. Induced hepatic stellate cell integrin, α8β1, enhances cellular contractility and TGFβ activity in liver fibrosis. J Pathol 2021;253:366-73. [PMID: 33433924 DOI: 10.1002/path.5618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
98 Lee C, Kim J, Han J, Oh D, Kim M, Jeong H, Kim T, Kim S, Kim JN, Seo Y, Suzuki A, Kim JH, Jung Y. Formyl peptide receptor 2 determines sex-specific differences in the progression of nonalcoholic fatty liver disease and steatohepatitis. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-28138-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
99 Yamamoto M, Yoshioka Y, Kitakaze T, Yamashita Y, Ashida H. Preventive effects of black soybean polyphenols on non-alcoholic fatty liver disease in three different mouse models. Food Funct 2022. [PMID: 35015019 DOI: 10.1039/d1fo03541j] [Reference Citation Analysis]
100 Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease? Adv Nutr 2020;11:1696-711. [PMID: 33191435 DOI: 10.1093/advances/nmaa081] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
101 Dall M, Hassing AS, Niu L, Nielsen TS, Ingerslev LR, Sulek K, Trammell SAJ, Gillum MP, Barrès R, Larsen S, Poulsen SS, Mann M, Ørskov C, Treebak JT. Hepatocyte-specific perturbation of NAD+ biosynthetic pathways in mice induces reversible nonalcoholic steatohepatitis-like phenotypes. J Biol Chem 2021;297:101388. [PMID: 34762911 DOI: 10.1016/j.jbc.2021.101388] [Reference Citation Analysis]
102 Takizawa N, Hironaka T, Mae K, Ueno T, Horii Y, Nagasaka A, Nakaya M. GPRC5B promotes collagen production in myofibroblasts. Biochem Biophys Res Commun 2021;561:180-6. [PMID: 34023784 DOI: 10.1016/j.bbrc.2021.05.035] [Reference Citation Analysis]
103 Shoji S, Maekawa M, Ogura J, Sato T, Mano N. Identification cholesterol metabolites altered before the onset of nonalcoholic steatohepatitis by targeted metabolomics. Biochim Biophys Acta Mol Cell Biol Lipids 2022;:159135. [PMID: 35217199 DOI: 10.1016/j.bbalip.2022.159135] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Toita R, Shimizu E, Kang J. Unique cellular interaction of macrophage-targeted liposomes potentiates anti-inflammatory activity. Chem Commun 2020;56:8253-6. [DOI: 10.1039/d0cc03320k] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
105 Heintz MM, McRee R, Kumar R, Baldwin WS. Gender differences in diet-induced steatotic disease in Cyp2b-null mice. PLoS One 2020;15:e0229896. [PMID: 32155178 DOI: 10.1371/journal.pone.0229896] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
106 Miyata S, Kawashima Y, Sakai M, Matsubayashi M, Motoki K, Miyajima Y, Watanabe Y, Chikamatsu N, Taniguchi T, Tokuyama R. Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists. Sci Rep 2021;11:9196. [PMID: 33911126 DOI: 10.1038/s41598-021-88493-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
107 Paka L, Smith DE, Jung D, McCormack S, Zhou P, Duan B, Li JS, Shi J, Hao YJ, Jiang K, Yamin M, Goldberg ID, Narayan P. Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease. World J Gastroenterol 2017; 23(23): 4181-4190 [PMID: 28694658 DOI: 10.3748/wjg.v23.i23.4181] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
108 Jahn D, Kircher S, Hermanns HM, Geier A. Animal models of NAFLD from a hepatologist's point of view. Biochim Biophys Acta Mol Basis Dis 2019;1865:943-53. [PMID: 29990551 DOI: 10.1016/j.bbadis.2018.06.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
109 Lu Y, Su X, Zhao M, Zhang Q, Liu C, Lai Q, Wu S, Fang A, Yang J, Chen X, Yao Y. Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH. PeerJ 2019;7:e8115. [PMID: 31879571 DOI: 10.7717/peerj.8115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
110 Hiroyama S, Rokugawa T, Ito M, Iimori H, Morita I, Maeda H, Fujisawa K, Matsunaga K, Shimosegawa E, Abe K. Quantitative evaluation of hepatic integrin αvβ3 expression by positron emission tomography imaging using 18F-FPP-RGD2 in rats with non-alcoholic steatohepatitis. EJNMMI Res 2020;10:118. [PMID: 33026561 DOI: 10.1186/s13550-020-00704-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Mehmood A, Zhao L, Wang Y, Pan F, Hao S, Zhang H, Iftikhar A, Usman M. Dietary anthocyanins as potential natural modulators for the prevention and treatment of non-alcoholic fatty liver disease: A comprehensive review. Food Res Int 2021;142:110180. [PMID: 33773656 DOI: 10.1016/j.foodres.2021.110180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
112 Bashyam A, Frangieh CJ, Raigani S, Sogo J, Bronson RT, Uygun K, Yeh H, Ausiello DA, Cima MJ. A portable single-sided magnetic-resonance sensor for the grading of liver steatosis and fibrosis. Nat Biomed Eng 2021;5:240-51. [PMID: 33257853 DOI: 10.1038/s41551-020-00638-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Honda M, Kimura C, Uede T, Kon S. Neutralizing antibody against osteopontin attenuates non-alcoholic steatohepatitis in mice. J Cell Commun Signal 2020;14:223-32. [PMID: 32062834 DOI: 10.1007/s12079-020-00554-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
114 Yadav AK, Sata TN, Verma D, Mishra AK, Sah AK, Hossain MM, Pant K, Venugopal SK. Free fatty acid-induced miR-181a-5p stimulates apoptosis by targeting XIAP and Bcl2 in hepatic cells. Life Sci 2022;:120625. [PMID: 35551953 DOI: 10.1016/j.lfs.2022.120625] [Reference Citation Analysis]
115 Jiang X, Zhang F, Ji X, Dong F, Yu H, Xue M, Qiu Y, Yang F, Hu X, Bao Z. Lipid-injured hepatocytes release sOPN to improve macrophage migration via CD44 engagement and pFak-NFκB signaling. Cytokine 2021;142:155474. [PMID: 33647584 DOI: 10.1016/j.cyto.2021.155474] [Reference Citation Analysis]
116 Parlati L, Régnier M, Guillou H, Postic C. New targets for NAFLD. JHEP Rep 2021;3:100346. [PMID: 34667947 DOI: 10.1016/j.jhepr.2021.100346] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Saito T, Watanabe A, Nakano M, Matsuo K. MALDI-TOF mass spectrometry imaging for N-glycans on FFPE tissue sections of mouse NASH liver through Sialic acid Benzylamidation. Glycoconj J 2021;38:167-75. [PMID: 33710478 DOI: 10.1007/s10719-021-09984-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
118 Erstad DJ, Farrar CT, Ghoshal S, Masia R, Ferreira DS, Chen YI, Choi JK, Wei L, Waghorn PA, Rotile NJ, Tu C, Graham-O'Regan KA, Sojoodi M, Li S, Li Y, Wang G, Corey KE, Or YS, Jiang L, Tanabe KK, Caravan P, Fuchs BC. Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist. Hepatol Commun 2018;2:821-35. [PMID: 30027140 DOI: 10.1002/hep4.1193] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
119 Pedersen HD, Galsgaard ED, Christoffersen BØ, Cirera S, Holst D, Fredholm M, Latta M. NASH-inducing Diets in Göttingen Minipigs. J Clin Exp Hepatol 2020;10:211-21. [PMID: 32405177 DOI: 10.1016/j.jceh.2019.09.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
120 Takumi S, Okamura K, Yanagisawa H, Sano T, Kobayashi Y, Nohara K. The effect of a methyl-deficient diet on the global DNA methylation and the DNA methylation regulatory pathways. J Appl Toxicol 2015;35:1550-6. [PMID: 25690533 DOI: 10.1002/jat.3117] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
121 Li S, Li X, Chen F, Liu M, Ning L, Yan Y, Zhang S, Huang S, Tu C. Nobiletin mitigates hepatocytes death, liver inflammation, and fibrosis in a murine model of NASH through modulating hepatic oxidative stress and mitochondrial dysfunction. J Nutr Biochem 2021;100:108888. [PMID: 34695558 DOI: 10.1016/j.jnutbio.2021.108888] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
122 Hwan Hong C, Ko MS, Kim JH, Cho H, Lee CH, Yoon JE, Yun JY, Baek IJ, Jang JE, Lee SE, Cho YK, Baek JY, Oh SJ, Lee BY, Lim JS, Lee J, Hartig SM, Conde de la Rosa L, Garcia-Ruiz C, Lee KU, Fernández-Checa JC, Choi JW, Kim S, Koh EH. Sphingosine 1-Phosphate Receptor 4 Promotes Nonalcoholic Steatohepatitis by Activating NLRP3 Inflammasome. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00252-6. [PMID: 34890841 DOI: 10.1016/j.jcmgh.2021.12.002] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
123 Zhang T, Hu J, Wang X, Zhao X, Li Z, Niu J, Steer CJ, Zheng G, Song G. MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-κB-TNFα pathway. J Hepatol 2019;70:87-96. [PMID: 30218679 DOI: 10.1016/j.jhep.2018.08.026] [Cited by in Crossref: 40] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
124 Karkucinska-Wieckowska A, Simoes ICM, Kalinowski P, Lebiedzinska-Arciszewska M, Zieniewicz K, Milkiewicz P, Górska-Ponikowska M, Pinton P, Malik AN, Krawczyk M, Oliveira PJ, Wieckowski MR. Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship. Eur J Clin Invest 2021;:e13622. [PMID: 34050922 DOI: 10.1111/eci.13622] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Harada S, Miyagi K, Obata T, Morimoto Y, Nakamoto K, Kim KI, Kim SK, Kim SR, Tokuyama S. Influence of hyperglycemia on liver inflammatory conditions in the early phase of non-alcoholic fatty liver disease in mice. J Pharm Pharmacol 2017;69:698-705. [PMID: 28220495 DOI: 10.1111/jphp.12705] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
126 Bloomer SA, Olivier AK, Bergmann OM, Mathahs MM, Broadhurst KA, Hicsasmaz H, Brown KE. Strain- and time-dependent alterations in hepatic iron metabolism in a murine model of nonalcoholic steatohepatitis. Cell Biochem Funct 2016;34:628-39. [PMID: 27935134 DOI: 10.1002/cbf.3238] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
127 Moustakas II, Katsarou A, Legaki AI, Pyrina I, Ntostoglou K, Papatheodoridi AM, Gercken B, Pateras IS, Gorgoulis VG, Koutsilieris M, Chavakis T, Chatzigeorgiou A. Hepatic Senescence Accompanies the Development of NAFLD in Non-Aged Mice Independently of Obesity. Int J Mol Sci 2021;22:3446. [PMID: 33810566 DOI: 10.3390/ijms22073446] [Reference Citation Analysis]
128 Hwang S, Ren T, Gao B. Obesity and binge alcohol intake are deadly combination to induce steatohepatitis: A model of high-fat diet and binge ethanol intake. Clin Mol Hepatol 2020;26:586-94. [PMID: 32937687 DOI: 10.3350/cmh.2020.0100] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
129 Farrell GC, Haczeyni F, Chitturi S. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease. Adv Exp Med Biol. 2018;1061:19-44. [PMID: 29956204 DOI: 10.1007/978-981-10-8684-7_3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 12.3] [Reference Citation Analysis]
130 Zhao P, Sun X, Chaggan C, Liao Z, In Wong K, He F, Singh S, Loomba R, Karin M, Witztum JL, Saltiel AR. An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis. Science 2020;367:652-60. [PMID: 32029622 DOI: 10.1126/science.aay0542] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 18.0] [Reference Citation Analysis]
131 Zeng QM, Li J. Diet-induced animal models of nonalcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2019; 27(13): 835-841 [DOI: 10.11569/wcjd.v27.i13.835] [Reference Citation Analysis]
132 Flores-Costa R, Alcaraz-Quiles J, Titos E, López-Vicario C, Casulleras M, Duran-Güell M, Rius B, Diaz A, Hall K, Shea C, Sarno R, Currie M, Masferrer JL, Clària J. The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis. Br J Pharmacol 2018;175:953-67. [PMID: 29281143 DOI: 10.1111/bph.14137] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
133 Miura K, Ishioka M, Iijima K. The Roles of the Gut Microbiota and Toll-like Receptors in Obesity and Nonalcoholic Fatty Liver Disease. J Obes Metab Syndr 2017;26:86-96. [PMID: 31089501 DOI: 10.7570/jomes.2017.26.2.86] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
134 Ma X, Huang Y, Ding Y, Shi L, Zhong X, Kang M, Li C. Analysis of piRNA expression spectra in a non-alcoholic fatty liver disease mouse model induced by a methionine- and choline-deficient diet. Exp Ther Med 2020;19:3829-39. [PMID: 32346447 DOI: 10.3892/etm.2020.8653] [Reference Citation Analysis]
135 Choi S, Kim JA, Li H, Jo SE, Lee H, Kim TH, Kim M, Kim SJ, Suh SH. Anti-inflammatory and anti-fibrotic effects of modafinil in nonalcoholic liver disease. Biomed Pharmacother 2021;144:112372. [PMID: 34794237 DOI: 10.1016/j.biopha.2021.112372] [Reference Citation Analysis]
136 Yang YM, Wang Z, Matsuda M, Seki E. Inhibition of hyaluronan synthesis by 4-methylumbelliferone ameliorates non-alcoholic steatohepatitis in choline-deficient L-amino acid-defined diet-induced murine model. Arch Pharm Res 2021;44:230-40. [PMID: 33486695 DOI: 10.1007/s12272-021-01309-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
137 Lee SR, Kwon SW, Kaya P, Lee YH, Lee JG, Kim G, Lee GS, Baek IJ, Hong EJ. Loss of progesterone receptor membrane component 1 promotes hepatic steatosis via the induced de novo lipogenesis. Sci Rep 2018;8:15711. [PMID: 30356113 DOI: 10.1038/s41598-018-34148-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
138 Cazanave SC, Warren AD, Pacula M, Touti F, Zagorska A, Gural N, Huang EK, Sherman S, Cheema M, Ibarra S, Bates J, Billin AN, Liles JT, Budas GR, Breckenridge DG, Tiniakos D, Ratziu V, Daly AK, Govaere O, Anstee QM, Gelrud L, Luther J, Chung RT, Corey KE, Winckler W, Bhatia S, Kwong GA. Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. Sci Transl Med 2021;13:eabe8939. [PMID: 34669440 DOI: 10.1126/scitranslmed.abe8939] [Reference Citation Analysis]
139 Czernuszewicz TJ, Aji AM, Moore CJ, Montgomery SA, Velasco B, Torres G, Anand KS, Johnson KA, Deal AM, Zukić D, McCormick M, Schnabl B, Gallippi CM, Dayton PA, Gessner RC. Development of a Robotic Shear Wave Elastography System for Noninvasive Staging of Liver Disease in Murine Models. Hepatol Commun 2022. [PMID: 35202510 DOI: 10.1002/hep4.1912] [Reference Citation Analysis]
140 Wei G, An P, Vaid KA, Nasser I, Huang P, Tan L, Zhao S, Schuppan D, Popov YV. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer. Am J Physiol Gastrointest Liver Physiol 2020;318:G174-88. [PMID: 31630534 DOI: 10.1152/ajpgi.00041.2019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
141 Li S, Ghoshal S, Sojoodi M, Arora G, Masia R, Erstad DJ, Lanuti M, Hoshida Y, Baumert TF, Tanabe KK, Fuchs BC. Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. J Gastrointest Surg. 2019;23:101-111. [PMID: 30367397 DOI: 10.1007/s11605-018-4004-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
142 Chella Krishnan K, Floyd RR, Sabir S, Jayasekera DW, Leon-Mimila PV, Jones AE, Cortez AA, Shravah V, Péterfy M, Stiles L, Canizales-Quinteros S, Divakaruni AS, Huertas-Vazquez A, Lusis AJ. Liver Pyruvate Kinase Promotes NAFLD/NASH in Both Mice and Humans in a Sex-Specific Manner. Cell Mol Gastroenterol Hepatol 2021;11:389-406. [PMID: 32942044 DOI: 10.1016/j.jcmgh.2020.09.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
143 Liu L, Liu C, Zhao M, Zhang Q, Lu Y, Liu P, Yang H, Yang J, Chen X, Yao Y. The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model. PLoS One 2020;15:e0243911. [PMID: 33326461 DOI: 10.1371/journal.pone.0243911] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
144 de Mingo Á, de Gregorio E, Moles A, Tarrats N, Tutusaus A, Colell A, Fernandez-Checa JC, Morales A, Marí M. Cysteine cathepsins control hepatic NF-κB-dependent inflammation via sirtuin-1 regulation. Cell Death Dis 2016;7:e2464. [PMID: 27831566 DOI: 10.1038/cddis.2016.368] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
145 Hartimath SV, Boominathan R, Soh V, Cheng P, Deng X, Chong YC, Yong FF, Tan PW, Han W, Robins EG, Goggi JL. Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH). Contrast Media Mol Imaging 2019;2019:6298128. [PMID: 31866798 DOI: 10.1155/2019/6298128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
146 Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol 2021. [PMID: 34741169 DOI: 10.1038/s41577-021-00639-3] [Reference Citation Analysis]
147 Hao X, Ma C, Xiang T, Ou L, Zeng Q. Associations Among Methylene Tetrahydrofolate Reductase rs1801133 C677T Gene Variant, Food Groups, and Non-alcoholic Fatty Liver Disease Risk in the Chinese Population. Front Genet 2021;12:568398. [PMID: 33679874 DOI: 10.3389/fgene.2021.568398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Oligschlaeger Y, Shiri-Sverdlov R. NAFLD Preclinical Models: More than a Handful, Less of a Concern? Biomedicines 2020;8:E28. [PMID: 32046285 DOI: 10.3390/biomedicines8020028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
149 Kawashita E, Ozaki T, Ishihara K, Kashiwada C, Akiba S. Endothelial group IVA phospholipase A2 promotes hepatic fibrosis with sinusoidal capillarization in the early stage of a non-alcoholic steatohepatitis in mice. Life Sciences 2022. [DOI: 10.1016/j.lfs.2022.120355] [Reference Citation Analysis]
150 He Z, Chen S, Pan T, Li A, Wang K, Lin Z, Liu W, Wang Y, Wang Y. Ginsenoside Rg2 Ameliorating CDAHFD-Induced Hepatic Fibrosis by Regulating AKT/mTOR-Mediated Autophagy. J Agric Food Chem 2022. [PMID: 35104139 DOI: 10.1021/acs.jafc.1c07578] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Hernández-Alvarez MI, Sebastián D, Vives S, Ivanova S, Bartoccioni P, Kakimoto P, Plana N, Veiga SR, Hernández V, Vasconcelos N, Peddinti G, Adrover A, Jové M, Pamplona R, Gordaliza-Alaguero I, Calvo E, Cabré N, Castro R, Kuzmanic A, Boutant M, Sala D, Hyotylainen T, Orešič M, Fort J, Errasti-Murugarren E, Rodrígues CMP, Orozco M, Joven J, Cantó C, Palacin M, Fernández-Veledo S, Vendrell J, Zorzano A. Deficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease. Cell 2019;177:881-895.e17. [PMID: 31051106 DOI: 10.1016/j.cell.2019.04.010] [Cited by in Crossref: 82] [Cited by in F6Publishing: 78] [Article Influence: 41.0] [Reference Citation Analysis]
152 Yoshihara T, Maruyama R, Shiozaki S, Yamamoto K, Kato SI, Nakamura Y, Tobita S. Visualization of Lipid Droplets in Living Cells and Fatty Livers of Mice Based on the Fluorescence of π-Extended Coumarin Using Fluorescence Lifetime Imaging Microscopy. Anal Chem 2020;92:4996-5003. [PMID: 32126762 DOI: 10.1021/acs.analchem.9b05184] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
153 Inomata Y, Oh J, Taniguchi K, Sugito N, Kawaguchi N, Hirokawa F, Lee S, Akao Y, Takai S, Kim K, Uchiyama K. Downregulation of miR-122-5p Activates Glycolysis via PKM2 in Kupffer Cells of Rat and Mouse Models of Non-Alcoholic Steatohepatitis. IJMS 2022;23:5230. [DOI: 10.3390/ijms23095230] [Reference Citation Analysis]
154 Radhakrishnan S, Ke JY, Pellizzon MA. Targeted Nutrient Modifications in Purified Diets Differentially Affect Nonalcoholic Fatty Liver Disease and Metabolic Disease Development in Rodent Models. Curr Dev Nutr 2020;4:nzaa078. [PMID: 32494762 DOI: 10.1093/cdn/nzaa078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
155 Hu M, Wang Y, Liu Z, Yu Z, Guan K, Liu M, Wang M, Tan J, Huang L. Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis. Nat Nanotechnol 2021;16:466-77. [PMID: 33495618 DOI: 10.1038/s41565-020-00836-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
156 Yasukagawa M, Shimada A, Shiozaki S, Tobita S, Yoshihara T. Phosphorescent Ir(III) complexes conjugated with oligoarginine peptides serve as optical probes for in vivo microvascular imaging. Sci Rep 2021;11:4733. [PMID: 33637825 DOI: 10.1038/s41598-021-84115-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
157 Hayashida M, Hashimoto K, Ishikawa T, Miyamoto Y. Vitronectin deficiency attenuates hepatic fibrosis in a non-alcoholic steatohepatitis-induced mouse model. Int J Exp Pathol 2019;100:72-82. [PMID: 30887659 DOI: 10.1111/iep.12306] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
158 Van Herck MA, Vonghia L, Francque SM. Animal Models of Nonalcoholic Fatty Liver Disease-A Starter's Guide. Nutrients. 2017;9:1072. [PMID: 28953222 DOI: 10.3390/nu9101072] [Cited by in Crossref: 113] [Cited by in F6Publishing: 106] [Article Influence: 22.6] [Reference Citation Analysis]
159 Bain G, Shannon KE, Huang F, Darlington J, Goulet L, Prodanovich P, Ma GL, Santini AM, Stein AJ, Lonergan D, King CD, Calderon I, Lai A, Hutchinson JH, Evans JF. Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis. J Pharmacol Exp Ther 2016;360:1-13. [DOI: 10.1124/jpet.116.237156] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
160 Noichi J, Ishiakawa T, Ichi I, Fujiwara Y. Effect of tocotrienol on the primary progression of nonalcoholic steatohepatitis in a mouse model. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-69] [Reference Citation Analysis]
161 Lee J, Byun J, Shim G, Oh Y. Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-29186-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Zhang Y, Lv J, Zhang J, Lv Z, Yu M. Lipidomic-based investigation into the therapeutic effects of polyene phosphatidylcholine and Babao Dan on rats with non-alcoholic fatty liver disease. Biomed Chromatogr 2021;:e5271. [PMID: 34727379 DOI: 10.1002/bmc.5271] [Reference Citation Analysis]
163 Hansen HH, Feigh M, Veidal SS, Rigbolt KT, Vrang N, Fosgerau K. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discov Today. 2017;22:1707-1718. [PMID: 28687459 DOI: 10.1016/j.drudis.2017.06.007] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 18.4] [Reference Citation Analysis]
164 Hussien NI, El-kerdasy HI, Ibrahim ME. Protective effect of rimonabant, a canabinoid receptor 1 antagonist, on nonalcoholic fatty liver disease in a rat model through modulation of the hepatic expression of activin A and follistatin. Can J Physiol Pharmacol 2017;95:1433-41. [DOI: 10.1139/cjpp-2017-0070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
165 Abe N, Kato S, Tsuchida T, Sugimoto K, Saito R, Verschuren L, Kleemann R, Oka K. Longitudinal characterization of diet-induced genetic murine models of non-alcoholic steatohepatitis with metabolic, histological, and transcriptomic hallmarks of human patients. Biol Open 2019;8:bio041251. [PMID: 31023717 DOI: 10.1242/bio.041251] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
166 Azuma YT, Fujita T, Izawa T, Hirota K, Nishiyama K, Ikegami A, Aoyama T, Ike M, Ushikai Y, Kuwamura M, Fujii H, Tsuneyama K. IL-19 Contributes to the Development of Nonalcoholic Steatohepatitis by Altering Lipid Metabolism. Cells 2021;10:3513. [PMID: 34944021 DOI: 10.3390/cells10123513] [Reference Citation Analysis]
167 Koboziev I, Scoggin S, Gong X, Mirzaei P, Zabet-Moghaddam M, Yosofvand M, Moussa H, Jones-Hall Y, Moustaid-Moussa N. Effects of Curcumin in a Mouse Model of Very High Fat Diet-Induced Obesity. Biomolecules 2020;10:E1368. [PMID: 32992936 DOI: 10.3390/biom10101368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
168 Xu Q, Fan Y, Loor JJ, Liang Y, Lv H, Sun X, Jia H, Xu C. Aloin protects mice from diet-induced non-alcoholic steatohepatitis via activation of Nrf2/HO-1 signaling. Food Funct 2021;12:696-705. [PMID: 33410857 DOI: 10.1039/d0fo02684k] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
169 Furuta K, Guo Q, Pavelko KD, Lee JH, Robertson KD, Nakao Y, Melek J, Shah VH, Hirsova P, Ibrahim SH. Lipid-induced endothelial vascular cell adhesion molecule 1 promotes nonalcoholic steatohepatitis pathogenesis. J Clin Invest 2021;131:143690. [PMID: 33476308 DOI: 10.1172/JCI143690] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
170 Santhekadur PK, Kumar DP, Sanyal AJ. Preclinical models of non-alcoholic fatty liver disease. J Hepatol 2018;68:230-7. [PMID: 29128391 DOI: 10.1016/j.jhep.2017.10.031] [Cited by in Crossref: 125] [Cited by in F6Publishing: 117] [Article Influence: 25.0] [Reference Citation Analysis]
171 Brown ZJ, Heinrich B, Greten TF. Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. Nat Rev Gastroenterol Hepatol 2018;15:536-54. [DOI: 10.1038/s41575-018-0033-6] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 17.5] [Reference Citation Analysis]
172 Sakai T, Ohba H, Nishiyama S, Kakiuchi T, Inoue O, Tsukada H. Sensitive and early detection of mitochondrial dysfunction in the liver of NASH model mice by PET imaging with 18F-BCPP-BF. EJNMMI Res 2018;8:61. [PMID: 30014266 DOI: 10.1186/s13550-018-0420-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
173 Su Y, Lu S, Hou C, Ren K, Wang M, Liu X, Zhao S, Liu X. Mitigation of liver fibrosis via hepatic stellate cells mitochondrial apoptosis induced by metformin. Int Immunopharmacol 2022;108:108683. [PMID: 35344814 DOI: 10.1016/j.intimp.2022.108683] [Reference Citation Analysis]
174 Patel V, Joharapurkar A, Kshirsagar S, Sutariya B, Patel M, Pandey D, Patel H, Ranvir R, Kadam S, Patel D, Bahekar R, Jain M. Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition. Chemico-Biological Interactions 2018;282:13-21. [DOI: 10.1016/j.cbi.2018.01.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]